Stock Track | BioAge Labs Soars 25% After Successful $198 Million IPO

Stock Track09-27

Shares of BioAge Labs Inc. (BIOA) surged 25% on Wednesday after the clinical-stage biopharmaceutical company priced its upsized initial public offering (IPO), raising $198 million by selling 11 million shares at $18 each.

The Richmond, California-based company is looking to capitalize on the surging popularity of weight-loss drugs, which are expected to become a $150 billion market by the early 2030s. BioAge is developing azelaprag, a pill intended to be used in combination with leading weight-loss treatments such as Eli Lilly's Zepbound and Novo Nordisk's Wegovy.

BioAge has initiated a mid-stage study testing azelaprag in combination with Zepbound, with data expected in the third quarter of 2025. The company also plans to start a second mid-stage trial pairing azelaprag with Wegovy in the first half of 2025, with results anticipated in the second half of 2026. Proceeds from the successful IPO will help fund the advancement of azelaprag into late-stage clinical studies.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1132193437?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-09-27 00:16","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1132193437","market":"us","top_or_hot":-1,"title":"Stock Track | BioAge Labs Soars 25% After Successful $198 Million IPO","media":"Stock Track","content":"<p>Shares of BioAge Labs Inc. (BIOA) surged 25% on Wednesday after the clinical-stage biopharmaceutical company priced its upsized initial public offering (IPO), raising $198 million by selling 11 million shares at $18 each.</p>\n\n<p>The Richmond, California-based company is looking to capitalize on the surging popularity of weight-loss drugs, which are expected to become a $150 billion market by the early 2030s. BioAge is developing azelaprag, a pill intended to be used in combination with leading weight-loss treatments such as Eli Lilly's Zepbound and Novo Nordisk's Wegovy.</p>\n\n<p>BioAge has initiated a mid-stage study testing azelaprag in combination with Zepbound, with data expected in the third quarter of 2025. The company also plans to start a second mid-stage trial pairing azelaprag with Wegovy in the first half of 2025, with results anticipated in the second half of 2026. Proceeds from the successful IPO will help fund the advancement of azelaprag into late-stage clinical studies.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | BioAge Labs Soars 25% After Successful $198 Million IPO</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | BioAge Labs Soars 25% After Successful $198 Million IPO\n</h2>\n\n<h4 class=\"meta\">\n\n2024-09-27 00:16 北京时间&nbsp;&nbsp;&nbsp;<strong>Stock Track</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shares of BioAge Labs Inc. (BIOA) surged 25% on Wednesday after the clinical-stage biopharmaceutical company priced its upsized initial public offering (IPO), raising $198 million by selling 11 ...</p>\n\n<a href=\"\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BIOA","symbol_name":"BioAge Labs Inc.","start_time":0,"source_url":"","article_id":"1132193437","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1132193437","pubTimestamp":1727367393,"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of BioAge Labs Inc.  surged 25% on Wednesday after the clinical-stage biopharmaceutical company priced its upsized initial public offering , raising $198 million by selling 11 million shares at $18 each.The Richmond, California-based company is looking to capitalize on the surging popularity of weight-loss drugs, which are expected to become a $150 billion market by the early 2030s. BioAge is developing azelaprag, a pill intended to be used in combination with leading weight-loss treatmen","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BIOA":"BioAge Labs Inc."},"translate_title":"BioAge Labs成功IPO 1.98亿美元后股价飙升25%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BIOA":1},"content_text":"Shares of BioAge Labs Inc. (BIOA) surged 25% on Wednesday after the clinical-stage biopharmaceutical company priced its upsized initial public offering (IPO), raising $198 million by selling 11 million shares at $18 each.\nThe Richmond, California-based company is looking to capitalize on the surging popularity of weight-loss drugs, which are expected to become a $150 billion market by the early 2030s. BioAge is developing azelaprag, a pill intended to be used in combination with leading weight-loss treatments such as Eli Lilly's Zepbound and Novo Nordisk's Wegovy.\nBioAge has initiated a mid-stage study testing azelaprag in combination with Zepbound, with data expected in the third quarter of 2025. The company also plans to start a second mid-stage trial pairing azelaprag with Wegovy in the first half of 2025, with results anticipated in the second half of 2026. Proceeds from the successful IPO will help fund the advancement of azelaprag into late-stage clinical studies.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.0","shortVersion":"4.29.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1132193437"}